Pronetics™

Our Prostate Cancer Gene Panel

North Central Jersey Diagnostics & DNA Technologies (NCJ DNA) brings the convenience and accessibility of genetic testing to individuals who have an increased risk of inherited prostate cancer. Next generation sequencing identifies high-risk individuals and provides the insights for early diagnosis of cancer and proactive care.

Using this targeted genomic Next generation sequencing, we screen for germ-line mutations in 22 genes already known to confer high risk for cancer in individuals diagnosed with prostate cancer. This is a sub-panel of our Supernetics™ 134 Comprehensive Cancer Gene Panel.

Our Pronetics™ panel consists of the following high-risk cancer genes: ATM, BRCA1, BRCA2, CANCA1D, CHEK2, ELAC2, EPCAM, HNF1A, HNF1B, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51D, SPINK1, TP53, WRN and WT1.

A genetic contribution to prostate cancer risk has been documented, and knowledge about the molecular genetics of the disease is increasing. Genetic involvement in prostate cancer includes the following suggestive factors: 1) multiple first-degree relatives with prostate cancer, 2) including three successive generations with prostate cancer in the maternal and paternal lines; 3) early-age onset prostate cancer and 4) prostate cancer with a family history of other cancers (breast, ovarian, pancreatic). Additional factors include smoking, obesity, vasectomy, chemical exposure, STDs, alcohol use, increased age and African-American ethnicity.

Close Menu